9:20 am Chair’s Opening Remarks
9:30 am Reserved for Spotlight Partner
Mid to Late Clinical Development (PHASE 2/3)
9:40 am Multi-Format Session: Pitfalls to Avoid in Late-Stage Cannabinoid Clinical Trials – a Post-Mortem of Cannabinoid Clinical Trials
Synopsis
- 20 minute presentation
- Roundtable discussion on tears, tantrums, frustrations of in-human clinical cannabinoid trials, followed by panel discussion
10:40 am Reserved for Exhibition Partner
11:10 am Morning Break & Speed Networking
11:54 am
Novel Cannabinoid Compounds
Novel Cannabinoid Compounds
11:55 am Faah Inhibitors: The Innocent Pay for the Guilty
Synopsis
- Discuss past research conducted on FAAH inhibitors by major players and small biotech companies
- Address concerns over safety
- Look at why so many companies are rediscovering this molecule now
Drug Delivery Technologies
Drug Delivery Technologies
12:25 pm Delivery Platforms to Produce Better Therapeutics
Synopsis
- Explore how cannabinoids, whilst potentiated to hold therapeutic benefit and administered in varying ways with both short and long-term side effects, more is not always better
- Evaluate how for cannabinoids to truly become a medicine, patient risk needs to be minimized and delivery platforms have the potential to mitigate this risk
- Understand NanoCelle® Medlab’s proprietary, patented delivery platform and how it will be used as an example of low efficacious dose with minimal side effects in over 1100 Australian patients
Effective Targeting
Effective Targeting
11:55 am Target Identification/Validation with ECS Drug
Synopsis
- In the context of Medpharm’s current research into degenerative disease, discuss key ideas involved in the
phase 1 study design process - Consider key target identification principles
Biomarker Identification & Validation
Biomarker Identification & Validation
12:25 pm A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder
Synopsis
- Examine how successful autism spectrum disorder (ASD) treatment is challenging due to subjective evaluation of changes in social interaction, language and communication ability, and repetitive behaviors, observed by clinician and family members of the individual with ASD
- Study metabolic biomarkers and how they are an attractive method to quantify and personalize medical cannabis (MC) treatment for individuals with ASD
- Investigate how such biomarkers also present an opportunity to understand the underlying mechanism of action (MOA) of MC treatment in individuals with ASD
- Inspect how Cannabis-Responsive™ biomarkers in saliva provide a scientifically validated technology to objectively quantify the impact of MC and can indicate the MOA in children with ASD treated under physician supervision
12:55 pm Lunch Break & Poster Session
2:30 pm Complex Chemically Active Transdermal Emulsion System Systemically Delivering CBD & THC Into Healthy Volunteers
Synopsis
- Take a look at novel chemically active transdermal emulsion system used for systemic delivery of therapeutic concentrations of CBD and THC
- Examine the structure of CTA Health Canada bioavailability study in healthy volunteers conducted in Dec/Jan
- Review of in vivo patient bioavailability data including blood concentration curves for the delivery of CBD and THC over a 12-hour period
3:00 pm Cannabinoid Side Effects: A Downer in Search of Mitigation
Synopsis
- Identify side effects of cannabinoid use clinically
- Discuss how to address side effects of cannabinoid use clinically
Combing RWE & Clinical Research to Identify Therapeutic Opportunity
Combing RWE & Clinical Research to Identify Therapeutic Opportunity
2:30 pm Aggregating Large-Scale RWE to Reveal Health Effects of Major & Minor Phytocannabinoids
Synopsis
- Analyze the known effects of minor phytocannabinoids from randomized controlled trials published in peerreviewed journals
- Understand how pragmatic trials can be used to study phytocannabinoids cheaper and faster
- Explore the known effects of major and minor phytocannabinoids from unpublished RWE
Establishing an IP Strategy
Establishing an IP Strategy
3:00 pm Designing a Robust IP Strategy
Synopsis
- Hear perspectives on IP strategy and enforcement from key opinion leaders at the heart of the cannabis and cannabinoid field
- Understand the IP lifecycle, and how work at one stage can influence another. For example, what your team can do during prosecution to prepare a company for litigation
3:30 pm Afternoon Break
4:00 pm Therapeutic Potential of Cannabinoids in Combination Cancer Therapy
Synopsis
- Understand how the current known therapeutic potential of cannabinoids as antiemetic, antianorexic and antiseizure remedies can be useful in a drug combo for cancer
- Discuss what studies are needed for this potential to be capitalized on
Funding for Cannabinoid Research
Funding for Cannabinoid Research
4:00 pm Accessing Investment to Further Cannabinoid Research
Synopsis
- Discuss how to attract funds from cannabis-focused investment funds, as well as traditional mainstream investment banks
- Identify current trends in stock values of medcann/ cannabinoid pharmaceuticals